Perrigo Sets Strategy For Global Infant Formula Growth
This article was originally published in The Tan Sheet
The private labeler’s more than 60 planned product launches include Codex-compliant infant formulas. The firm also sees marketing formula in plastic containers as a U.S. sales driver.
You may also be interested in...
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc
One of firms targeted in eight most recent warnings published since early September to OTC drug manufacturers, Zhao Qing Longda Biotechnology Co. in China, was dinged for both failing to respond to a request for records and for concerns about its production with DEG and EG.